Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
Identifieur interne : 002F94 ( Istex/Curation ); précédent : 002F93; suivant : 002F95Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
Auteurs : Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Y. Agid [France] ; X. Lataste [Suisse]Source :
- Movement Disorders [ 0885-3185 ] ; 1992.
English descriptors
Abstract
A selective dopamine D1‐receptor agonist, CY 208‐243, was administered to 23 de novo patients who had had Parkinson disease (PD) for ≤3 months. The drug was first used as monotherapy and then in some patients in combination with a dopamine D2‐receptor agonist, bromocriptine. Results showed that CY 208‐243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. The addition of bromocriptine ≤15 mg to CY 208‐243 did not result in additional improvement, but this might be due to the short duration of treatment and the low doses of bromocriptine. The study was prematurely discontinued for safety reasons. We conclude that D1‐receptor stimulation may result in improvement of motor disability in PD.
Url:
DOI: 10.1002/mds.870070309
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F94
Links to Exploration step
ISTEX:60B926BEB9684EE72D9E09F83E49236DC2BB3CE3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease</title><author><name sortKey="Emre" sort="Emre" uniqKey="Emre" last="Emre">Emre</name><affiliation wicri:level="1"><mods:affiliation>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel</wicri:regionArea></affiliation></author><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Turku, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Service de Neurologie, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name><affiliation wicri:level="2"><mods:affiliation>The National Hospital for Nervous Diseases, London, England</mods:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The National Hospital for Nervous Diseases, London</wicri:cityArea></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name><affiliation wicri:level="1"><mods:affiliation>Hĉpital de la Salpêtrière, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hĉpital de la Salpêtrière, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X." last="Lataste">X. Lataste</name><affiliation wicri:level="1"><mods:affiliation>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:60B926BEB9684EE72D9E09F83E49236DC2BB3CE3</idno><date when="1992" year="1992">1992</date><idno type="doi">10.1002/mds.870070309</idno><idno type="url">https://api.istex.fr/document/60B926BEB9684EE72D9E09F83E49236DC2BB3CE3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F94</idno><idno type="wicri:Area/Istex/Curation">002F94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease</title><author><name sortKey="Emre" sort="Emre" uniqKey="Emre" last="Emre">Emre</name><affiliation wicri:level="1"><mods:affiliation>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel</wicri:regionArea></affiliation></author><author><name sortKey="Rinne, U K" sort="Rinne, U K" uniqKey="Rinne U" first="U. K." last="Rinne">U. K. Rinne</name><affiliation wicri:level="1"><mods:affiliation>Department of Neurology, University of Turku, Finland</mods:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Neurology, University of Turku</wicri:regionArea></affiliation></author><author><name sortKey="Rascol, A" sort="Rascol, A" uniqKey="Rascol A" first="A." last="Rascol">A. Rascol</name><affiliation wicri:level="1"><mods:affiliation>Service de Neurologie, Hôpital Purpan, Toulouse, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Hôpital Purpan, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name><affiliation wicri:level="2"><mods:affiliation>The National Hospital for Nervous Diseases, London, England</mods:affiliation><country>Royaume-Uni</country><placeName><region type="country">Angleterre</region></placeName><wicri:cityArea>The National Hospital for Nervous Diseases, London</wicri:cityArea></affiliation></author><author><name sortKey="Agid, Y" sort="Agid, Y" uniqKey="Agid Y" first="Y." last="Agid">Y. Agid</name><affiliation wicri:level="1"><mods:affiliation>Hĉpital de la Salpêtrière, Paris, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hĉpital de la Salpêtrière, Paris</wicri:regionArea></affiliation></author><author><name sortKey="Lataste, X" sort="Lataste, X" uniqKey="Lataste X" first="X." last="Lataste">X. Lataste</name><affiliation wicri:level="1"><mods:affiliation>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel, Switzerland</mods:affiliation><country xml:lang="fr">Suisse</country><wicri:regionArea>Clinical Research, CNS Department, Sandoz Pharma Ltd., Basel</wicri:regionArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1992">1992</date><biblScope unit="vol">7</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="239">239</biblScope><biblScope unit="page" to="243">243</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">60B926BEB9684EE72D9E09F83E49236DC2BB3CE3</idno><idno type="DOI">10.1002/mds.870070309</idno><idno type="ArticleID">MDS870070309</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>D1‐receptor agonists</term><term>Dopamine agonists</term><term>Parkinson disease</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A selective dopamine D1‐receptor agonist, CY 208‐243, was administered to 23 de novo patients who had had Parkinson disease (PD) for ≤3 months. The drug was first used as monotherapy and then in some patients in combination with a dopamine D2‐receptor agonist, bromocriptine. Results showed that CY 208‐243 exerted a mild antiparkinsonian action, and tremor was the main symptom that consistently improved. The addition of bromocriptine ≤15 mg to CY 208‐243 did not result in additional improvement, but this might be due to the short duration of treatment and the low doses of bromocriptine. The study was prematurely discontinued for safety reasons. We conclude that D1‐receptor stimulation may result in improvement of motor disability in PD.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 002F94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Curation
|type= RBID
|clé= ISTEX:60B926BEB9684EE72D9E09F83E49236DC2BB3CE3
|texte= Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease
}}
| This area was generated with Dilib version V0.6.23. |  |